DONALD W NIBBELINK
Medical Practice in Lansdale, PA
License number
Pennsylvania MD016333E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Lansdale, PA 19446
Personal information
See more information about DONALD W NIBBELINK at radaris.comName
Address
Phone
17 Park Dr, Lansdale, PA 19446
Lansdale, PA
17 Park Dr, Lansdale, PA 19446
17 Park Ave, Lansdale, PA 19446
Professional information
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4832957, May 23, 1989
Filed:
Jul 25, 1988
Appl. No.:
7/223861
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combinations presently employed.
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4983400, Jan 8, 1991
Filed:
Dec 1, 1989
Appl. No.:
7/444222
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 922, A61K 926, A61K 3178
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levodopa combination presently employed.
Controlled Release Combination Of Carbidopa/Levodopa
US Patent:
4900755, Feb 13, 1990
Filed:
Feb 24, 1989
Appl. No.:
7/315057
Inventors:
Robert E. Dempski - Dresher PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Edward C. Scholtz - King of Prussia PA
Donald W. Nibbelink - Lansdale PA
Scott A. Reines - New Hope PA
Assignee:
Merck & Co. - Rahway NJ
International Classification:
A61K 920, A61K 922, A61K 926
US Classification:
424469
Abstract:
A matrix or monolithic drug delivery system for the controlled release of carbidopa and levodopa consists of the two drugs uniformly dispersed in a polymer vehicle at a concentration that is greater than the solubility of either drug in the polymer. Treatment of parkinsonism with the controlled release formulation provides several advantages over treatment with the standard carbidopa/levidopa combinations presently employed.